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Abstract
Anonymous screening of lymphoreticular tissues removed during routine surgery has been applied to estimate
the UK population prevalence of asymptomatic vCJD prion infection. The retrospective study of Hilton et al (J
Pathol 2004; 203: 733–739) found accumulation of abnormal prion protein in three formalin-fixed appendix
specimens. This led to an estimated UK prevalence of vCJD infection of ∼1 in 4000, which remains the key
evidence supporting current risk reduction measures to reduce iatrogenic transmission of vCJD prions in the
UK. Confirmatory testing of these positives has been hampered by the inability to perform immunoblotting of
formalin-fixed tissue. Animal transmission studies offer the potential for ‘gold standard’ confirmatory testing but
are limited by both transmission barrier effects and known effects of fixation on scrapie prion titre in experimental
models. Here we report the effects of fixation on brain and lymphoreticular human vCJD prions and comparative
bioassay of two of the three prevalence study formalin-fixed, paraffin-embedded (FFPE) appendix specimens using
transgenic mice expressing human prion protein (PrP). While transgenic mice expressing human PrP 129M readily
reported vCJD prion infection after inoculation with frozen vCJD brain or appendix, and also FFPE vCJD brain,
no infectivity was detected in FFPE vCJD spleen. No prion transmission was observed from either of the FFPE
appendix specimens. The absence of detectable infectivity in fixed, known positive vCJD lymphoreticular tissue
precludes interpreting negative transmissions from vCJD prevalence study appendix specimens. In this context,
the Hilton et al study should continue to inform risk assessment pending the outcome of larger-scale studies on
discarded surgical tissues and autopsy samples.
Copyright  2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Experimental confirmation that variant Creutzfeldt–
Jakob disease (vCJD) [1] is caused by the same prion
strain as that causing bovine spongiform encephalopa-
thy (BSE) in cattle [2–5] led to global concern that
human exposure to BSE prions posed a significant
threat to public health [6–8]. While the risk of new
dietary exposure to BSE prions in the UK is now
remote [9], the majority of the UK population may have
been exposed during the late 1980s and early 1990s.
While the number of recorded clinical cases (∼200)
has been relatively low, and epidemiological modelling
argued against a large number of additional cases [10],
it is increasingly clear that sub-clinical carrier states
of prion infection may occur, particularly on crossing
a species barrier and with low-dose exposure [11–15].
Modelling cannot estimate the number of sub-clinically
infected carriers, and the discrepancy between num-
bers of clinical cases and prevalence estimates from
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population screening remains unexplained [16–19].
Incubation periods in human prion infections, even
in the absence of a species barrier, may exceed five
decades [6,20,21], and multiple genetic loci in addition
to the PrP gene are known to influence prion incubation
periods in mice [22–25] and susceptibility in humans
[26,27]. Asymptomatically infected carriers appear to
have transmitted vCJD prion infection and disease to
others via blood transfusion [28–30] or blood prod-
ucts [31]. Other iatrogenic routes, notably from con-
taminated surgical instruments, present a potential risk
[6,8,32].
In the absence of a blood test for human prion dis-
ease, the distinct phenotype of vCJD has provided the
basis for investigating infection prevalence within the
UK population. The peripheral pathogenesis of vCJD
differs significantly from that of classical CJD, inher-
ited prion disease, and kuru, with disease-related PrP
(PrPSc) being uniformly and prominently detected in a
range of lymphoreticular tissues at autopsy [33–37]. To
date, antemortem tonsil biopsy has shown 100% sen-
sitivity and specificity for diagnosis of clinical vCJD
[30,33,34], and the fact that lymphoreticular prion
infection is not a feature of iatrogenic CJD [33,36]
or kuru [21,38] argues that the distinct pathogenesis of
vCJD relates to the effect of prion strain rather than
to a peripheral route of infection [21,38,39]. Because
lymphoreticular colonization is thought to precede neu-
roinvasion in vCJD, and indeed has been detected in
archived surgical samples removed prior to the devel-
opment of overt clinical symptoms [40,41], anonymous
screening of lymphoreticular tissues removed during
routine surgery appears to offer a practical means to
estimate the population prevalence of asymptomatic
vCJD infection. However, the sensitivity and speci-
ficity of such testing during the pre-clinical incubation
period or in chronic carriers (who may have a dis-
tinct pathogenesis which conceivably might not involve
the same degree of lymphoreticular colonization) are
unknown. Although peripheral tissue involvement in
recently identified cases of variable protease-sensitive
prionopathy [42–45] has not yet been defined, the
apparent rarity of this condition would not be expected
to confound estimates of UK vCJD prevalence.
To date, three prevalence studies have been reported
[41,46,47]. The first study used immunohistochemistry
to retrospectively examine 11 247 appendicectomy and
1427 tonsillectomy specimens that had been archived
as formalin-fixed tissue blocks [41]. Positive lym-
phoreticular accumulation of abnormal PrP was found
in three appendixes from 10 278 specimens in a patient
birth cohort of 1961–1985, giving a population preva-
lence in this age group of 292 (95% confidence inter-
val 60–853) per million [41,47]. Subsequent studies
have prospectively examined only tonsil as this tis-
sue can be readily obtained from large numbers of
routine tonsillectomy procedures. Tonsil appeared to
be a more sensitive reporter of clinical vCJD infec-
tion than appendix in one study [48], although not in
another [36]. The first prospective pilot scale study
of 2000 specimens found no evidence for tonsillar
accumulation of abnormal PrP using high sensitivity
methods [46]. More recently, a much larger national
study of 63 007 tonsils reported no positive specimens
using enzyme immunoassays to detect disease-related
PrP [47]. To confirm the reliability of this result, all
specimens in the 1961–1985 birth cohort (9160 ton-
sils) plus controls were tested by immunohistochem-
istry [19,49]. Three specimens showed some initial
reactivity, but for two this was concluded to be non-
specific. For the third, one strongly positive follicle was
identified on two slides from adjacent sections using
different anti-PrP antibodies. However, subsequent re-
sampling of this specimen revealed no further reactiv-
ity by either immunohistochemistry or immunoblotting
[19,49]. Notably, an incidence of either zero or one
positive in the 1961–1985 birth cohort in these large-
scale studies of tonsil does not significantly alter the
infection prevalence estimated by the original study of
appendix specimens [19,47,49].
Inevitably, the failure to identify an unequivocally
positive sample in more recent prospective studies has
meant that the positive appendix specimens identi-
fied by Hilton et al have been the subject of consid-
erable debate [17–19,41]. Central to this is whether
the identified immuno-reactivity truly reflects authen-
tic prion infection. Interpretation has been hampered
by the inability to do confirmatory immunoblotting
of formalin-fixed tissue and by the fact that two of
the three positive specimens that could be analysed
were from individuals with a PRNP codon 129 valine
homozygous genotype [50]. Polymorphism at residue
129 of human PrP [encoding either methionine (M) or
valine (V)] powerfully affects susceptibility to human
prion diseases, with residue 129 acting to restrict
the propagation of particular prion strains through
conformational selection [6,51,52] and heterozygosity
conferring resistance by inhibiting homologous pro-
tein–protein interactions [52–54]. To date, all patients
with neuropathologically confirmed vCJD have been
PRNP codon 129 methionine homozygotes [7,26] and
have a remarkably uniform and distinct neuropatho-
logical phenotype defined by the presence of abundant
florid PrP plaques [1] and the propagation of type 4
PrPSc [2,55] in the brain.
Transgenic modelling has provided a molecular
explanation for these findings by showing that human
PrP 129 valine is unable to propagate the vCJD
prion strain [51] and that BSE- or vCJD-challenged
human PrP 129V transgenic mice propagate novel
prion strains that have not yet been identified in
humans [3,39,51]. It is unclear whether humans of
the PRNP 129VV genotype following infection with
BSE prions would develop a clinical disease and if
so, what clinicopathological phenotype would result
[7,8,51]. Thus, in the absence of any natural history
of BSE prion infection in humans with a PRNP codon
129VV genotype, no positive control tissue exists for
comparison with the appendix specimens identified in
the prevalence screen. A clinical vCJD case in a PRNP
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codon 129 MV heterozygote has been reported, but no
tissue biopsy or autopsy was performed [56]. In the
present study, we have therefore sought to investigate
these specimens further by attempting to transmit
prion infection from formalin-fixed tissue to transgenic
mice overexpressing human PrP. Owing to the paucity
of tissue available, it was not possible to inoculate
different lines of transgenic mice expressing either
human PrP 129 methionine or valine. Based on our
experience of the transmission properties of vCJD and
BSE prions, we chose to use Tg45 mice homozygous
for 129 methionine [5]. These mice faithfully propagate
the molecular and neuropathological phenotype of
vCJD following primary challenge with either vCJD
prions [5,57] or BSE prions [5] and are known to
be sensitive to infection when inoculated with vCJD
peripheral tissue containing PrPSc at a concentration
104.7-fold lower than in brain [57]. Importantly, the
novel prion strain (associated with type 5 PrPSc) that
is generated in vCJD-challenged human PrP 129V
transgenic mice also transmits infection efficiently to
transgenic mice expressing human PrP 129M [51].
Materials and methods
Ethical issues
Storage and biochemical analysis of human tissue sam-
ples and transmission studies to mice were performed
with consent from patients or relatives under approval
from the Local Research Ethics Committee of UCL
Institute of Neurology/National Hospital for Neurology
and Neurosurgery and the code of practice specified
in the Human Tissue Authority licence held by UCL
Institute of Neurology. Work with mice was performed
under licence granted by the UK Home Office and
conformed to University College London institutional
guidelines. All procedures were carried out in microbi-
ological containment level 3 facilities with strict adher-
ence to safety protocols.
Preparation of inocula
Frozen brain (frontal cortex) and appendix (full thick-
ness tissue) from a single neuropathologically con-
firmed vCJD patient [48] were prepared as 10% w/v
homogenates in Dulbecco’s sterile phosphate-buffered
saline lacking Ca2+ and Mg2+ ions (D-PBS) by either
serial passage through needles of decreasing diameter
(brain) or the use of a Duall tissue grinder (appendix).
PrPSc-positive 10% w/v homogenates [48] were diluted
to 1% w/v with D-PBS and passed through a 25-gauge
syringe needle prior to storage at −70 ◦C. Formalin-
fixed, paraffin-embedded (FFPE) tissues that had not
been exposed to formic acid were each available as
three tissue sections each of approximate dimensions
4 µm × 0.5 cm × 1 cm mounted on glass slides.
FFPE tissues for investigation comprised vCJD brain
and vCJD spleen and two of the three abnormal PrP-
positive appendix specimens (both PRNP codon 129
valine homozygous genotype) identified in the preva-
lence screen by Hilton et al [41]. Tissue was recovered
by sequential treatment, firstly to remove paraffin by
immersion in two changes of xylene for 5 min, fol-
lowed by sequential immersion for 5 min in graded
ethanol (100% × 2 and 70% × 1), after which tissue
was re-hydrated by immersion in D-PBS for 5 min.
Each of the cognate tissue sections was scraped from
the glass slides and pooled in 300 µl of D-PBS and
passaged through 16-, 19-, 21-, and 23-gauge syringe
needles prior to storage at −70 ◦C. We estimate that
this procedure produced tissue homogenates of a con-
centration of ∼0.2% w/v.
Transmission studies
Transgenic mice homozygous for a human PrP 129
methionine (M) transgene array and murine PrP null
alleles (Prnpo/o) designated Tg(HuPrP129M+/+
Prnpo/o)-45 (129 MM Tg45 mice) have been described
previously [5,57,58]. Inocula (30 µl of tissue homoge-
nate in D-PBS as described above) were injected intra-
cerebrally into groups of ten 129 MM Tg45 mice as
described elsewhere [5] and thereafter examined daily
and were killed if they exhibited signs of distress or
once a clinical diagnosis of prion disease was estab-
lished. Brains from inoculated mice were analysed by
high sensitivity immunoblotting and by neuropatholog-
ical examination.
Immunohistochemistry
Transgenic mouse brain was analysed with anti-PrP
monoclonal antibody ICSM 35 (D-Gen Ltd, London,
UK), using a Ventana automated immunohistochemical
staining machine (Ventana Medical Systems Inc, Tuc-
son, AZ, USA) as described previously [38,59]. Briefly,
tissue was fixed in 10% buffered formal saline followed
by incubation in 98% formic acid for 1 h. Follow-
ing further washing for 24 h in 10% buffered formal
saline, tissue samples were processed and paraffin wax-
embedded. Sections were cut at a nominal thickness of
4 µm, treated with 98% formic acid for 5 min, and
then boiled in a low ionic strength buffer (2.1 mM
Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8)
for 20 min. Abnormal PrP accumulation was exam-
ined using anti-PrP monoclonal ICSM 35 followed
by a biotinylated anti-mouse IgG secondary antibody
(iView Biotinylated Ig, Ventana Medical Systems Inc)
and an avidin–biotin horseradish peroxidase conjugate
(iView SA-HRP, Ventana Medical Systems Inc) before
development with 3′,3-diaminobenzidine tetrachloride
as the chromogen (iView DAB, Ventana Medical Sys-
tems Inc). Haematoxylin was used as the counterstain.
Haematoxylin and eosin staining of serial sections was
performed using conventional methods [59]. Appropri-
ate controls were used throughout.
Copyright  2010 Pathological Society of Great Britain and Ireland. J Pathol 2011; 223: 511–518
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
514 JDF Wadsworth et al
Figure 1. Molecular strain typing of vCJD brain and appendix
transmissions in transgenic mice. (A–C) Immunoblots of
proteinase-K-treated homogenates of vCJD tissues or 129 MM
Tg45 transgenic mouse brain analysed by enhanced chemilu-
minescence with anti-PrP monoclonal antibody 3F4. All brain
samples were analysed directly (between 1 and 8 µl of 10% w/v
homogenate). vCJD appendix was pre-concentrated with sodium
phosphotungstic acid from 500 µl of 10% w/v homogenate.
(A) vCJD brain and appendix. Densitometry of this blot showed
that the relative proportion of di-glycosylated PrP in PrPSc in
the brain or appendix was 46% or 74%, respectively. (B) vCJD
brain compared with 129 MM Tg45 mouse brain after transmis-
sion of vCJD brain or appendix. (C) vCJD brain compared with
129 MM Tg45 mouse brain after transmission of formalin-fixed,
paraffin-embedded (FFPE) vCJD brain.
Table 1. Summary of transmissions of human tissues to 129 MM
Tg45 transgenic mice
Clinical Incubation period Total attack
Inoculum∗ signs (days ± SEM) rate†
vCJD brain 4/10 396 ± 22 9/10
vCJD appendix 1/7 457 4/7
FFPE vCJD brain 3/9 580 ± 21 5/9
FFPE vCJD spleen 0/8 >359‡ 0/8
FFPE prevalence 0/4 >609 0/4
appendix 1
FFPE prevalence 0/8 >405§ 0/8
appendix 2
∗Mice were inoculated with 30 µl of either 1% w/v vCJD brain or vCJD
appendix homogenate, or ∼0.2% w/v formalin-fixed, paraffin-embedded (FFPE)
tissue homogenate. †Total attack rate is defined as the total number of both
clinically affected and sub-clinically infected mice as a proportion of the
number of inoculated mice. Sub-clinical prion infection was assessed by analysis
for PrPSc (by either direct immunoblotting or after sodium phosphotungstic
acid precipitation of 250 µl of 10% w/v brain homogenate) and also by
immunohistochemical examination of brain. ‡Mice were culled at 360, 442, 442,
610, 610, 610, 610, and 610 days post-inoculation. §Mice were culled at 406,
451, 561, 610, 610, 610, 610, and 610 days post-inoculation.
Immunoblotting
Human or transgenic mouse tissues prepared as 10%
w/v homogenates in D-PBS were analysed by pro-
teinase K digestion (50 or 100 µg/ml final protease
concentration, 1 h, 37 ◦C) and immunoblotting with
anti-PrP monoclonal antibody 3F4 [60] using high
sensitivity enhanced chemiluminescence as described
previously [34,59]. For analysis of PrP glycoforms,
blots were developed in chemifluorescent substrate
(AttoPhos; Promega, Madison, WI, USA) and visual-
ized on a Storm 840 phosphoimager (GE Healthcare,
Little Chalfont, UK) using ImageQuaNT software (GE
Healthcare) [34,61]. Sodium phosphotungstic acid pre-
cipitation of PrPSc from tissue homogenate [62] was
performed as described previously [34,59].
Results
Previously we have reported the comparison of PrPSc
in brain and appendix from the same vCJD patient [48].
PrPSc in appendix was at a concentration ∼0.5% of that
present in brain [48] and was distinct from type 4 PrPSc
in brain, being characterized by a greater predominance
of di-glycosylated PrP (Figure 1A) closely similar to
that seen in tonsil and other lymphoreticular tissues
in vCJD [33,34,36,37,57]. These PrPSc-positive tissue
homogenates were used as positive controls for trans-
mission studies in comparison to FFPE tissue spec-
imens. Consistent with our previous findings [5,57],
intra-cerebral challenge of 129 MM Tg45 transgenic
mice with vCJD brain homogenate resulted in efficient
transmission of prion infection, with nine of ten inoc-
ulated mice scored as affected (Table 1). Four mice
developed clinical prion disease with a mean incuba-
tion period of 396 ± 22 days, while five other recip-
ients were sub-clinically infected (Table 1). The sin-
gle mouse scored as non-affected was culled, due to
inter-current illness at 280 days post-inoculation. All
nine infected mice had detectable PrPSc in brain that
showed a predominance of di-glycosylated PrP, and
accurate molecular strain typing was possible with four
samples, which confirmed the propagation of type 4
PrPSc (Figure 1B). In two of these brains, the presence
of abundant florid PrP plaques was demonstrated by
immunohistochemistry (Figure 2).
In comparison, and consistent with a lower concen-
tration of PrPSc in the inoculum, vCJD appendix trans-
mitted infection to 129 MM Tg45 mice with lower effi-
ciency. Four of seven inoculated mice were infected,
but only a single mouse developed clinical prion dis-
ease at 457 days post-inoculation (Table 1). The three
mice scored as non-affected were culled between 314
and 395 days post-inoculation. All four infected mice
had detectable PrPSc in brain that showed a predomi-
nance of di-glycosylated PrP, and three of these sam-
ples had PrPSc at sufficient concentration to permit
accurate molecular strain typing. This analysis showed
the propagation of type 4 PrPSc with no statistically
significant difference in the PrPSc glycoform ratio from
that seen in mice inoculated with vCJD brain (Table 2).
All three vCJD appendix-inoculated 129 MM Tg45
mice propagating high levels of type 4 PrPSc showed
the presence of florid PrP plaques in the brain by
immunohistochemistry (Figure 2). Thus, despite a dif-
ference in the glycoform ratio of PrPSc between vCJD
brain and appendix (Figure 1A), congruent transmis-
sion of the vCJD prion strain was seen in human PrP
129M transgenic mice characterized by the propaga-
tion of type 4 PrPSc and the occurrence of florid PrP
plaques in the brain.
While transmission of sporadic Creutzfeldt–
Jakob disease prions from formalin-fixed human brain
tissue to primates has been reported [63,64], to date
there have been no data concerning the effect of
formaldehyde on vCJD prions. We found that FFPE
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Figure 2. Neuropathological analysis of transgenic mouse brain. Transmission of vCJD brain homogenate, vCJD appendix homogenate,
and formalin-fixed, paraffin-embedded (FFPE) vCJD brain to 129 MM Tg45 mice. Haematoxylin- and eosin-stained sections (H&E) show
spongiform neurodegeneration in the cortex, including florid plaques that show abnormal PrP immunoreactivity (PrP) stained with anti-PrP
monoclonal antibody ICSM 35. Scale bar: H&E, 40 µm; PrP, 100 µm.
Table 2. Glycoform analysis of type 4 PrPSc propagated in the
brains of 129 MM Tg45 mice after transmission of vCJD brain or
appendix
Transmission Transmission
from from
PrP glycoform∗ brain appendix p value†
Di-glycosylated 55 ± 2 53 ± 3 0.15
Mono-glycosylated 30 ± 1 32 ± 3 0.23
Non-glycosylated 15 ± 2 15 ± 1 0.75
∗Relative proportion of each PrP glycoform (mean ± SD %) in type 4 PrPSc
propagated in the brains of 129 MM Tg45 transgenic mice inoculated with vCJD
brain (n = 4 mice) or appendix (n = 3 mice). †Unpaired two-tailed t-test.
vCJD brain transmitted infection to five of nine inocu-
lated 129 MM Tg45 mice without an apparent change
in prion strain properties. Three inoculated mice devel-
oped clinical prion disease, with a mean incubation
period of 580 ± 21 days, while two other recipients
were sub-clinically infected (Table 1). The four mice
scored as non-affected were culled between 540 and
610 days post-inoculation. All five infected mice had
positive PrP immunohistochemistry, and in three brains
prominent florid PrP plaques were observed (Figure 2).
Accurate molecular strain typing was possible with
two brains, which confirmed the propagation of type
4 PrPSc (Figure 1C).
Although the strain properties of vCJD prions are
preserved after exposure to formaldehyde, the unknown
level of prion infectivity present in the starting vCJD
brain tissue prevents us from commenting on how for-
malin fixation and subsequent processing may have
affected vCJD prion titre. However, the reduced attack
rate and more prolonged mean incubation period
observed with the FFPE vCJD brain compared with the
control vCJD brain homogenate are consistent with a
significantly reduced prion titre. In this regard, forma-
lin fixation of prion-infected hamster brain followed by
histological processing in the absence of exposure to
formic acid has been reported to reduce prion infectiv-
ity between 2 and 3 logs [65,66].
In contrast to FFPE vCJD brain, FFPE vCJD spleen
and both of the FFPE abnormal PrP-positive appendix
specimens failed to transmit prion infection to 129 MM
Tg45 mice (Table 1). Exhaustive examination of brains
from mice at up to 610 days post-inoculation failed
to reveal the presence of PrPSc after sodium phospho-
tungstic acid precipitation or the presence of abnor-
mal PrP deposition by immunohistochemistry (data not
shown).
Discussion
Current UK Department of Health risk assessment and
risk management are based to a large extent on the
results of the Hilton et al study [17–19]. Fundamental
to this is whether the three positives identified by PrP
immunohistochemistry are ‘true positives’ indicating
vCJD prion infection. In this study, we have attempted
to transmit prion infectivity from FFPE tissue sections
derived from two abnormal PrP-positive appendix
specimens identified in the retrospective vCJD preva-
lence screen of Hilton et al [41]. While transgenic
mice expressing human PrP 129M reported vCJD prion
infection after inoculation with frozen vCJD brain or
appendix and also FFPE vCJD brain, no prion trans-
mission was observed from FFPE vCJD spleen or the
FFPE appendix specimens. However, these negative
findings cannot be interpreted, as the levels of infec-
tivity in the positive control lymphoreticular tissue fol-
lowing formalin fixation were below the detection limit
of our assay. It is entirely possible, therefore, that the
Hilton et al positives were indeed prion-infected and
that a lower titre in these pre-clinical tissues and/or the
effect of formalin fixation precluded detection by our
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bioassay. Unless more sensitive assays for vCJD pri-
ons become available, verification of the estimated UK
prevalence of vCJD infection will have to come from
future prevalence studies [17–19,47].
Although the present findings are not informative
with regard to vCJD prevalence, two results are of
some importance. Firstly, we have demonstrated that
the strain properties of vCJD prions do not appear
to be affected by tissue fixation with formaldehyde
or by exposure to other chemicals that are commonly
used during histological processing. Secondly, we have
shown that prions associated with distinct PrPSc glyco-
types in vCJD brain (type 4) [2] or lymphoreticular
tissues (type 4t) [33,34] do not transmit disease with
distinct prion strain properties. These findings are in
agreement with two other recent studies that have also
shown congruent prion strain properties after transmis-
sion of brain or lymphoid tissue from sheep scrapie
to bank voles [67] or from vCJD to wild-type mice
[68]. Prion strains may comprise an ensemble or quasi-
species maintained under selection pressure in a host
and the populations of which may therefore differ
in different tissues [52,69]. According to this general
model [52], even if a distinct prion strain were prop-
agating in lymphoreticular as opposed to CNS tissue,
it would revert to the brain-specific strain type on pas-
sage in transgenic mouse brain. Thus, based on the
current findings and other published data [30,70] it
appears that molecular and neuropathological examina-
tion will not be able to differentiate between primary
vCJD cases resulting from exposure to BSE prions and
secondary cases resulting from iatrogenic exposure to
vCJD-infected peripheral tissues.
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